Drug Trial Radar · NCT02405091
Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia
Last checked: Nov 20, 2026Latest source record: Nov 30, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
167
Actual
Start
Mar 2015
Primary completion
Mar 2017
Study completion Mar 2017
Sponsor
- Lead sponsor
- Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
- Sponsor type
- Industry
- First posted
- Apr 1, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 3, open-label, study to evaluate the safety and tolerability of NBI-98854 administered once daily (qd) for a total of 48 weeks of treatment. This study will enroll approximately 150 medically stable male and female subjects with clinical diagnoses of schizophrenia or schizoaffective disorder with neuroleptic-induced TD or mood disorder with neuroleptic-induced TD.
Conditions
- Tardive Dyskinesia
Interventions
NBI-98854Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Monitored for Long-Term Safety of ValbenazineTime frame: 52 weeks
Locations
48 sites in 3 countries. Site status is shown where the registry gives one.
Site not named
Anaheim, California
Site not named
Glendale, California
Site not named
Irvine, California
Site not named
Long Beach, California
Site not named
Los Angeles, California
Site not named
Oakland, California
Site not named
San Bernardino, California
Site not named
San Diego, California
Site not named
Torrance, California
Site not named
Hockessin, Delaware
Site not named
Bradenton, Florida
Site not named
Hialeah, Florida
Site not named
Kissimmee, Florida
Site not named
Miami, Florida
Site not named
North Miami, Florida
Site not named
Orlando, Florida
Site not named
Honolulu, Hawaii
Site not named
Chicago, Illinois
Site not named
Shreveport, Louisiana
Site not named
Natick, Massachusetts
Site not named
Worcester, Massachusetts
Site not named
Ann Arbor, Michigan
Site not named
St Louis, Missouri
Site not named
Lincoln, Nebraska
Site not named
Omaha, Nebraska
Site not named
Nashua, New Hampshire
Site not named
Buffalo, New York
Site not named
New York, New York
Site not named
Rochester, New York
Site not named
High Point, North Carolina
Site not named
Dayton, Ohio
Site not named
Oklahoma City, Oklahoma
Site not named
Conshohocken, Pennsylvania
Site not named
Norristown, Pennsylvania
Site not named
Phoenixville, Pennsylvania
Site not named
Scranton, Pennsylvania
Site not named
DeSoto, Texas
Site not named
Fort Worth, Texas
Site not named
Houston, Texas
Site not named
Irving, Texas
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.